TROPION-Lung01 Study Design and Baseline demographics

Patient Disposition Disposition, n (%) Dato-DXd Docetaxel N=297 N=290 Treatment status Ongoing on study treatment 52 (18) 17 (6) 245 (83) 273 (94) Discontinued from study treatment Treatment duration 118 (40) 168 (58) 0-3 months 73 (25) 66 (23) >3 to ≤6 months 47 (16) 34 (12) >6 to ≤9 months 59 (20) 22 (8) >9 months Primary reason for treatment discontinuation 39 (13) 46 (16) Adverse event Progressive disease 173 (58) 180 (62) 9 (3) 11 (4) Clinical progression Withdrawal/physician decision 12 (4) 23 (8) 10 (3) 10 (3) Death 2 (1) 3 (1) Other Median study follow-up: Dato-DXd - 13.1 months; docetaxel - 13.0 months Daiichi-Sankyo 8

View entire presentation